762 related articles for article (PubMed ID: 28991932)
61. Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.
Verma RK; Sriramaneni R; Pandey M; Chaudhury H; Gorain B; Gupta G
Panminerva Med; 2018 Dec; 60(4):224-225. PubMed ID: 29856185
[No Abstract] [Full Text] [Related]
62. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
63. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
[TBL] [Abstract][Full Text] [Related]
64. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
[TBL] [Abstract][Full Text] [Related]
65. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
Boyle JG; Livingstone R; Petrie JR
Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
[TBL] [Abstract][Full Text] [Related]
66. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.
Fahrbach JL; Fu H; Shurzinske L; Skrivanek Z; Martin S
Int J Clin Pract; 2016 Mar; 70(3):218-21. PubMed ID: 26916354
[TBL] [Abstract][Full Text] [Related]
67. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T; Kubo M; Takahashi K; Wamata R; Iwamoto Y; Iwamoto H; Katakura Y; Sanada J; Fushimi Y; Shimoda M; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2024; 2024():5880589. PubMed ID: 38223524
[TBL] [Abstract][Full Text] [Related]
68. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
69. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study.
Singh P; Taufeeq M; Pesavento TE; Washburn K; Walsh D; Meng S
Diabetes Obes Metab; 2020 May; 22(5):879-884. PubMed ID: 31943645
[TBL] [Abstract][Full Text] [Related]
70. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
Takase T; Nakamura A; Yamamoto C; Nomoto H; Miya A; Dannoura M; Cho KY; Kurihara Y; Manda N; Aoki S; Atsumi T; Miyoshi H
J Diabetes Investig; 2019 May; 10(3):699-705. PubMed ID: 30076787
[TBL] [Abstract][Full Text] [Related]
71. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
[TBL] [Abstract][Full Text] [Related]
72. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
Cai TT; Li HQ; Jiang LL; Wang HY; Luo MH; Su XF; Ma JH
Biomed Res Int; 2021; 2021():3361309. PubMed ID: 34580638
[TBL] [Abstract][Full Text] [Related]
73. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang L; Li J; Zeng H; Liu J
Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
[TBL] [Abstract][Full Text] [Related]
74. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
75. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
Lorenz M; Evers A; Wagner M
Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288
[TBL] [Abstract][Full Text] [Related]
76. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T; Katakura Y; Shimoda M; Kawasaki F; Yamabe M; Tatsumi F; Matsuki M; Iwamoto Y; Anno T; Fushimi Y; Kamei S; Kimura Y; Nakanishi S; Mune T; Kaku K; Kaneto H;
Diabetes Obes Metab; 2023 Dec; 25(12):3632-3647. PubMed ID: 37646192
[TBL] [Abstract][Full Text] [Related]
77. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
78. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å; Fridhammar A
J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
[No Abstract] [Full Text] [Related]
80. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Mabilleau G; Pereira M; Chenu C
J Endocrinol; 2018 Jan; 236(1):R29-R42. PubMed ID: 28855317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
